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Abstract
We examined the geospatial dimension of delays to diagnosis of breast cancer in a pro-
spective study of 1541 women newly diagnosed in the African Breast Cancer—Dispar-
ities in Outcomes (ABC-DO) Study. Women were recruited at cancer treatment facilities
in Namibia, Nigeria, Uganda and Zambia. The baseline interview included information
used to generate the geospatial features: urban/rural residence, travel mode to treatment
facility and straight-line distances from home to first-care provider and to diagnostic/
treatment facility, categorized into country/ethnicity (population)-specific quartiles. These
factors were investigated in relation to delay in diagnosis (≥3 months since first symptom)
and late stage at diagnosis (TNM: III, IV) using logistic regression, adjusted for population
group and sociodemographic characteristics. The median (interquartile range) distances
to first provider and diagnostic and treatment facilities were 5 (1-37), 17 (3-105) and 62
(5-289) km, respectively. The majority had a delay in diagnosis (74%) and diagnosis at late
stage (64%). Distance to first provider was not associated with delay in diagnosis or late
stage at diagnosis. Rural residence was associated with delay, but the association did not
persist after adjustment for sociodemographic characteristics. Distance to the diagnostic/
treatment facility was associated with delay (highest vs lowest quartile: odds ratio
(OR) = 1.56, 95% confidence interval (CI) = 1.08-2.27) and late stage (overall: OR = 1.47,
CI = 1.05-2.06; without Nigerian hospitals where mostly local residents were treated:
OR = 1.73, CI = 1.18-2.54). These findings underscore the need for measures addressing
the geospatial barriers to early diagnosis in sub-Saharan African settings, including provid-
ing transport or travel allowance and decentralizing diagnostic services.
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1 | INTRODUCTION
Breast cancer is the second most cause of cancer death in women in
sub-Saharan Africa (SSA)1 and is expected to increase by more than
100% by 2040.2 Although breast cancer has excellent prognosis in
high-income settings owing to significant improvements in early diag-
nosis and treatment, survival from this disease in SSA remains poor.3,4
Explicitly, 5-year survival is >85% in high-resource settings including
North America, Sweden, France, and Australia vs about 59% in SSA
settings.3,5 To reduce this gap and curtail the predicted increase in
breast cancer deaths in SSA, efforts are needed to improve access to
quality breast cancer care including diagnostics and treatment.
The poorer survival in SSA is largely attributable to advanced dis-
ease at presentation,3,4 which has been found to be associated with
both patient-level barriers (eg, low level of education, a lack of breast
cancer knowledge, poor health-seeking behaviors) and system-level
barriers (eg, referral pathways).6-11 Compounding educational, cul-
tural, socioeconomic and health systems' barriers to reaching cancer
diagnostic and treatment services is the geospatial dimension of
healthcare access in SSA settings. Notably, many African countries
have only a few, or even a single, cancer treatment facility, which,
coupled with their immense size (ie, 23 of Africa's 54 countries are
larger than 500 000 m2, the area of France), means that patients need
to travel large distances to reach cancer diagnostic and treatment
facilities, incurring financial and logistic challenges.
A systematic review of 27 studies (of which only one is from
SSA,12 namely from South Africa) on distance as a barrier to cancer
diagnosis and treatment concluded that patients who live far from
hospitals and need to travel more than 50 miles/80 km (1 hour driv-
ing) or more are more likely to have an advanced disease at diagnosis,
inappropriate treatment, a worse prognosis and poorer quality of life
compared to those living closer to hospitals.13 However, data on
geospatial barriers to cancer diagnosis and treatment are scarce in
regions of SSA other than South Africa although a similar phenome-
non has been observed between large physical distance to healthcare
services and underutilization of obstetrics care14 as well as unmet sur-
gical needs.15
Given the utility of geospatial information in identifying gaps in
healthcare access to inform public health planning including the devel-
opment of cancer control measures, comprehensive geospatial studies
on cancer care and outcomes are needed in SSA. We, therefore,
aimed to characterize the geospatial dimensions of a woman's path-
way to breast cancer diagnosis and examine their associations with
time from symptom recognition to diagnosis and disease stage at
diagnosis within the wide-ranging multicountry prospective African
Breast Cancer—Disparities in Outcomes (ABC-DO) study.
2 | METHODS
The ABC-DO study was approved by the ethics committees of all
involved institutions: International Agency for Research on Cancer
(IEC 13-19, IEC15-18), London School of Hygiene and Tropical
Medicine (6459), Federal Medical Centre Owerri, Abia State Univer-
sity Teaching Hospital, University of Zambia Biomedical Research
Ethics Committee (004-08-15), Uganda National Council for Science
and Technology (HS 1588) and the Ministry of Health and Social Ser-
vices of Namibia (17/3/3).
2.1 | Study population
The ABC-DO study protocol has been described in detail elsewhere.16
Briefly, ABC-DO is a prospective study of outcomes after breast can-
cer diagnosis among patients consecutively recruited in five SSA
countries. One country, South Africa, was not included in the present
analysis due to a different data collection system, and the geospatial
influence on stage at diagnosis has already been investigated at that
site.12 The following recruitment centers are included: the Windhoek
Central Hospital in Namibia; the Cancer Diseases Hospital and Uni-
versity Teaching Hospital in Lusaka, and the Kabwe General Hospital
in Kabwe, Zambia; the Mulago Hospital and the Uganda Cancer Insti-
tute in Kampala, Uganda; and the Abia State University Teaching Hos-
pital and the Maranatha private clinic, both in Aba, and the Federal
Medical Centre in Owerri, Nigeria. The participating hospitals vary in
terms of their catchment populations (ie, national referral hospitals in
Namibia, Uganda and Zambia; state-wide for the Nigerian hospitals;
regional for the Kabwe General Hospital, Zambia).
In all countries, women aged ≥18 years who were newly admitted
with histologically confirmed or suspected breast cancer at the partici-
pating hospitals were invited to participate in the study. Recruitment
was conducted from September-December 2014 to April 2017 in
Namibia, Uganda and Nigeria and from May 2016 to September 2017
in Zambia. Women were included irrespective of current address
(including foreign residents to capture the reality in this setting) and
irrespective of ability to pay for or intention to undergo further treat-
ment. Out of 1637 potentially eligible women, 10 refused to partici-
pate, 2 were too ill, 2 passed away prior to being enrolled and 82
(mostly in Nigeria) had nonmalignant disease, leaving 1541 eligible
What's new?
Survival from breast cancer is poor in sub-Saharan Africa,
due largely to the high proportion of women who are diag-
nosed at advanced stages. In this study, the authors exam-
ined geospatial information to assess women's prediagnostic
journey to breast cancer diagnosis, with special attention to
delays in diagnosis, in the regions of Namibia, Nigeria,
Uganda, and Zambia. Geospatial factors particularly long
travel distances to diagnostic and treatment facilities were
identified as major barriers to early diagnosis. The findings
underscore the need for policies to address these barriers to
ensure breast cancer diagnosis at a curable stage.
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consenting women with histopathological/cytological (90%) or clinical
diagnosis of breast cancer. All 1541 women provided a written
informed consent or, if illiterate, a fingerprint. Five distinct population
groups were defined for the present analysis according to country of
recruitment and, for Namibia only, ethnicity: Namibian-black, Namib-
ian-non-black, Nigerian, Ugandan and Zambian women.
2.2 | Data collection
At the time of recruitment, each woman completed an interview
with a study research assistant. Women were asked about demo-
graphics, socioeconomic status (ie, possession of nine specific items,
such as home ownership, indoor water, flush toilet, electricity, vehi-
cle, used to create a socioeconomic position [SEP] score) and aware-
ness about breast cancer (five questions used to create a breast
cancer awareness score as the total number of correct answers).
Women were also asked about their prediagnostic journey (ie, from
first symptom recognition through to diagnosis) including date of
first symptom recognition, location of residential home, urbanization
of the area of residence, location of each healthcare provider visited
and type of providers she visited prior to reaching the recruitment
hospital (ie, formal: private doctor, private hospital, community clinic,
public hospital; informal: traditional healer, spiritual healer, home or
community care provider, pharmacists, other), outcome of each visit
(eg, being referred to another provider/facility, being reassured and
told not to worry, being told she has breast cancer), transport and
time taken to travel from home to the recruitment hospital, and self-
perceived barriers to reaching the hospital (eg, transport, distance,
fear of dying).
Information on TNM breast cancer stage at diagnosis was
extracted from clinical records, using a standardized study proforma.
The date of diagnosis was defined according to the European Net-
work of Cancer Registries guidelines,17 where date of biopsy/cytology
is prioritized over date of hospital presentation.
2.3 | Data analysis
The levels of detail of free-text home and provider addresses varied
from woman to woman, with some including street-level information
and others including only names of cities, regions, states or districts.
We geocoded these addresses, as well as addresses of diagnostic and
treatment locations, by searching for the locations in the National
Geospatial-Intelligence Agency GEOnet Names Server database and
assigning the corresponding geocoded longitude and latitude http://
geonames.nga.mil/gns/html/index.html. Where needed, search
engines, such as Google Maps, were used to aid geocoding. We pres-
ented the residential homes and the recruitment hospitals on a world
map (World Health Organization) using QGIS 3.4.14 (QGIS Develop-
ment Team, 2018). We then calculated straight-line distances in kilo-
meters from the residential home to the first healthcare provider
visited and from home to the diagnostic and treatment facilities (“geo-
dist” command in Stata 14, TX). In Namibia, the vast majority of diag-
noses were conducted via a network of pathological laboratories,
allowing tumor specimens to be obtained locally and couriered for his-
tological review by the Namibian Institute of Pathology in Windhoek.
Only after histological confirmation did the woman travel to the treat-
ment facility (where she was recruited and treated). Thus, for Namib-
ian women, the nearest pathological laboratory was geocoded and
used to calculate distance to diagnosis, unless they went directly to
the treatment facility. For the other settings, the locations of the labo-
ratories where diagnostic analytics were performed were used as the
location of diagnostic facility unless the location was in the proximity
of recruitment hospital. Distances were categorized into population-
specific quartiles. Predefined distance cut-off points were also used
for population-specific analyses.
Distance to the diagnostic facility was used for all delay analyses
and distance to the treatment facility, where staging was performed,
was used for all stage analyses. Travel time was not assessed in these
analyses because of a very low correlation between travel time and
distance, which likely resulted from women reporting their travel time
on the day of the visit rather than the travel time for the whole jour-
ney, which can be more than 1 day for some women. Logistic regres-
sion models were used to examine associations between each one of
the geospatial characteristics and each one of the two outcomes:
delay in diagnosis (a prediagnostic journey of 3 months or more, calcu-
lated as date of diagnosis minus date of first symptom recognition)
and late stage (Stages III-IV vs Stages 0-II). For distances, a test of lin-
ear trend was performed by fitting the continuous variables. Three
sets of odds ratios (ORs), and their corresponding 95% confidence
intervals (CIs), were estimated. First, each geospatial variable was
examined separately adjusting for population group only—this variable
was taken as an a priori confounder in all models except for the popu-
lation-specific analyses. Second, in addition to adjustment for popula-
tion group, geospatial variables were mutually adjusted. Third,
distance variable and rural residence variable were included in the
same model simultaneously while adjusting for population group and
other potential confounders, which were identified based on the asso-
ciations observed in relation to distance to treatment facility. Patient
type was not included as a confounder because it is highly dependent
on population group. Outcome of first visit was also not included as a
confounder because the group of women who went directly to the
treatment facility were more likely to be living nearer to the facility
and overadjustment was concerned. Self-reported barriers contribut-
ing to delays were not included because they were considered as
intermediate or subsequent to the outcome of interest.
Finally, we explored heterogeneity of the effects of distance with
diagnostic delay and with stage by population group, degree of urban-
ization (urban vs rural) and SEP. For Namibian women, we also com-
pared the odds of delay in diagnosis and late stage at diagnosis
according to residential location in Windhoek, or outside Windhoek
and within, or beyond, 50 km from the nearest pathological
laboratory.
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3 | RESULTS
3.1 | Cohort description
Out of 1541 women recruited to the study, 23 women (1.5%) were
missing information on residential address, leaving 1518 women in
the analytical sample. Of these, 33% were recruited from Windhoek,
Namibia, 27% from Kampala, Uganda, 13% from Kabwe and Lusaka,
Zambia, and 26% from Aba and Owerri, Nigeria. Nearly 4% traveled
from other neighboring countries. The mean age at breast cancer diag-
nosis was 50 years (SD: 13, range: 19-97 years), being the lowest in
Nigerian and Ugandan women (48 years) and the highest in Namibian
non-black women (57 years) (Table 1). The overall mean SEP score
was 4.4 (out of a possible maximum of 9), being the highest in Namib-
ian non-black women (7.8) and the lowest in Ugandan women (2.6).
The proportion who attended a technical school or university was the
highest for Namibian non-black (40%) and Nigerian (35%) women
(Table 1).
3.2 | Descriptives of prediagnostic journey
The majority of the women reported living in a town or city (urban)
except in Uganda where 73% reported living in a village or rural area
(rural) (Table 1). The median straight-line distance to first healthcare
provider was 5 km. At the first visit to a healthcare provider, 49% of
the women were referred to another provider/facility (31%) or told
that they had breast cancer (17%), whereas 32% were not suspected
of having breast cancer (28%) or underwent a test but never received
the results (5%). In Uganda and Nigeria, more women (13% and 7%,
respectively) visited an informal provider as their first point of contact
during the prediagnostic journey than in other populations (<1%). The
median straight-line distance to the treatment facility was 62 km and
was closest in Nigeria (6 km) and furthest in Namibian black women
(457 km). To reach the hospitals, women traveled by public transport/
foot (61%), car (16%) or other means. Maps of residential homes and
country-specific distribution of the straight-line distance from home
to the recruitment hospital are displayed in Figure 1.
Overall, 28% of the women reported experiencing some kind of
barrier, which they considered to have contributed to delay in
reaching the hospital. The distributions of perceived barriers varied
across the populations (Table 1). For example, the proportion of
women reporting distance to the hospital as a barrier was higher in
Uganda (13%), Zambia (11%) and Nigeria (10%) than in Namibia (black:
2%, non-black: 1%) despite the longer distances observed in Namibia.
A transport-related barrier was more commonly reported in Uganda
(24%) and Zambia (21%) than in the other countries. About 12% of
Nigerian women reported difficulty with making doctor's appoint-
ments, whereas only 2% to 4% did in the other populations.
Table 2 shows that population-specific quartiles of distance to
treatment facility were associated with certain sociodemographic
characteristics (ie, age at breast cancer diagnosis, educational level,
SEP [country-specific tertiles], patient type), outcome of first visit and,
as expected, with other geospatial variables (ie, degree of urbanization
of area of residence, distance to first healthcare provider, modes of
transport used to reach the first healthcare provider and the treat-
ment facility, and travel time to first healthcare provider and the treat-
ment facility). Breast cancer knowledge score, type of first provider
and the number of provider contacts did not differ significantly by dis-
tance. Of the self-reported barriers, transport, distance and difficulty
with making appointment/getting a hold of a health professional were
more commonly reported by women living farther away from the
hospital.
3.3 | Time to diagnosis of breast cancer and
disease stage at diagnosis
Median time from first symptom to diagnosis of breast cancer was
7 months (Table 1). The large majority (74%, among those with non-
missing information) of the women had a delay in diagnosis. Overall,
64% of the women were diagnosed at late stage, ranging from 25% in
Namibian non-black women to 76% in Nigerian women.
In analyses adjusted for population-group only, rural residence
and longer distance to diagnostic facility were associated with delay
in diagnosis (Table 3). After mutual adjustment, rural residence (OR:
1.40, 95% CI: 1.06-1.84) and distance (OR per 50 km increment:
OR = 1.04, 95% CI: 1.00-1.09, P trend: .048; highest vs lowest quar-
tile: OR: 1.57, 95% CI: 1.07-2.32) were found to be independently
associated with delay to diagnosis. There was some evidence that late
stage at diagnosis was positively associated with longer distance to
treatment facility (mutually adjusted OR per 50 km increment: 1.03,
95% CI: 1.01-1.06, P trend: .01; highest vs lowest quartile: 1.37, 95%
CI: 0.97-1.94) and inversely with highest quartile of distance to first
provider (vs lowest quartile: 0.75, 95% CI: 0.55-1.02), but not associ-
ated with distance to first provider when treated as a continuous vari-
able (mutually adjusted OR per 50 km increment: 1.01, 95% CI: 0.97-
1.06, P trend: .53) or rural residence (mutually adjusted OR: 1.11, 95%
CI: 0.86-1.43). Population-specific analysis revealed, however, some
heterogeneity in the direction and magnitude of the geospatial associ-
ations with late-stage disease, particularly so in Nigeria where, for
instance, rural residence was, in contrast to the other settings,
inversely associated with late-stage disease (OR: 0.49, 95% CI: 0.30-
0.79, Supplementary Table 1). Hence, in mutually adjusted analyses
restricted to non-Nigerian women, a positive association between
rural residence and late stage was revealed (OR: 1.45, 95% CI: 1.08-
1.94) and the positive association between distance to treatment
facility and late stage was strengthened slightly (OR for the highest vs
lowest quartile: 1.64, 95% CI: 1.11-2.44) (Table 3).
Further adjustment for sociodemographic variables (ie, age at
diagnosis, educational level, SEP [country-specific tertiles]) and modes
of transport used to reach the first healthcare provider, and the treat-
ment facility showed that distance to the diagnostic facility was the
only geospatial variable independently associated with delay in diag-
nosis (OR per 50 km increment: 1.05, 95% CI: 1.01-1.09, P trend: .02;
highest vs lowest quartile: 1.56, 95% CI: 1.08-2.27, Table 4) and late
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TABLE 1 Characteristics of ABC-DO women with a geocoded residential address and their prediagnostic journey to breast cancer diagnosis
Population Total Namibia black Namibia non-black Nigeria Uganda Zambia
Size of the catchment area (km2) N = national;
S = state
— 825 419 (N) 825 419 (N) 5530 (Imo S)
6320 (Aba S)
241 037 (N) 752 618
(N) 1547 (Kabwe)
No. of ABC-DO women (%) 1518 (100) 397 (26) 104 (7) 398 (26) 416 (27) 203 (13)
Sociodemographic characteristics
Age at breast cancer diagnosis, mean (SD) 50.3 (13.7) 52.9 (15.1) 57.3 (12.5) 48.6 (12.2) 48.1 (12.7) 49.6 (14.7)
Educational level
Primary school or less 681 (45) 209 (53) 13 (13) 110 (28) 242 (58) 107 (53)
Secondary/high school 509 (34) 136 (34) 49 (47) 147 (37) 123 (30) 54 (27)
Technical/university 328 (22) 52 (13) 42 (40) 141 (35) 51 (12) 42 (21)
Socioeconomic position score, mean (SD)a 4.4 (2.3) 5.0 (2.6) 7.8 (1.2) 4.9 (1.5) 2.6 (1.3) 4.0 (2.1)
Patient type
Public 935 (62) 286 (72) 41 (39) 2 (1) 403 (97) 203 (100)
Private without insurance 420 (28) 32 (8) 0 (0) 375 (94) 13 (3) 0 (0)
Private with insurance 163 (11) 79 (20) 63 (61) 21 (5) 0 (0) 0 (0)
Breast cancer knowledge score, mean (SD)b 3.5 (0.8) 3.5 (0.9) 4.1 (0.8) 3.5 (0.8) 3.4 (0.8) 3.3 (0.7)
Geospatial and other characteristics of prediagnostic
journey
Urbanization of area of residence
Urban (town or city) 814 (54) 224 (56) 93 (89) 254 (64) 111 (27) 132 (65)
Rural (rural or village) 704 (46) 173 (44) 11 (11) 144 (36) 305 (73) 71 (35)
Type of first HCP
Formal 1429 (94) 394 (99) 103 (99) 369 (93) 361 (87) 202 (100)
Informal 89 (6) 3 (1) 1 (1) 29 (7) 55 (13) 1 (0)
Outcome of visit to the first HCPc
Breast cancer not suspected/tests done but no
results
493 (32) 122 (31) 17 (16) 81 (20) 211 (51) 62 (31)
Breast cancer suspected/referral 741 (49) 273 (69) 87 (84) 102 (26) 144 (35) 135 (67)
Went directly to the treatment facility (ie, place
of recruitment)
284 (19) 2 (1) 0 (0) 215 (54) 61 (15) 6 (3)
No. of HCP contacts before reaching the
recruitment hospital, mean (SD)
2.0 (1.8) 2.8 (1.4) 2.6 (1.2) 0.6 (0.7) 2.9 (2.2) 1.5 (0.8)
Means of transport to the first HCP
Car 302 (20) 144 (36) 78 (75) 32 (8) 10 (2) 38 (19)
Public transport 861 (57) 132 (33) 6 (6) 358 (90) 272 (65) 93 (46)
Walk 292 (19) 114 (29) 18 (17) 8 (2) 87 (21) 65 (32)
Other, missing 63 (4) 7 (2) 2 (2) 0 (0) 47 (11) 7 (3)
Means of transport to the treatment facility
Car 240 (16) 85 (21) 75 (72) 35 (9) 12 (3) 33 (16)
Public transport, foot 920 (61) 82 (21) 12 (12) 363 (91) 303 (73) 160 (79)
Transport provided by hospital 232 (15) 213 (54) 15 (14) 0 (0) 1 (0) 3 (1)
Other, missing 126 (8) 17 (4) 2 (2) 0 (0) 100 (24) 7 (3)
Distance in kilometer (median, IQR) from home to:
First HCP 5 (1, 37) 1 (1, 44) 1 (1, 1) 7 (1, 29) 14 (4, 62) 4 (1, 62)
Diagnostic facilityd 17 (3, 105) 5 (1, 62) 1 (1, 12) 8.5 (2, 30) 76 (15, 191) 110 (5, 374)
Treatment facility 62 (5, 289) 457 (195, 583) 238 (1, 292) 6 (2, 28) 80.5 (15, 196) 156 (8, 374)
Travel time in hours (median, IQR) on the day of
visit to:
First HCP 0.7 (0.3, 1.5) 0.5 (0.3, 1.1) 0.2 (0.2, 0.3) 0.8 (0.5, 1.3) 1.0 (0.5, 2) 0.6 (0.3, 1.0)
Treatment facilitye 1.0 (0.7, 4.0) 5.1 (0.5, 10.6) 2.5 (0.3, 5.3) 1.0 (0.5, 1.0) 1.5 (1.0, 3.0) 1.0 (0.8, 1.8)
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stage at diagnosis (OR per 50 km increment: 1.04, 95% CI: 1.01-1.06,
P trend: .004; highest vs lowest quartile: OR: 1.47, 95% CI: 1.05-2.06),
with the late-stage associations for the quartiles being somewhat
strengthened in analysis restricted to non-Nigerian women (OR for
the highest vs lowest quartile: 1.73, 95% CI: 1.18-2.54). For both out-
comes, significant associations were not found with rural residence
after adjustment for distance to diagnostic/treatment facility and the
aforementioned covariates. A forest plot of the estimated ORs associ-
ated with geospatial variables is shown in Figure 2.
Upon examination of effect modification of the effects of dis-
tance on delay to diagnosis and on late stage at diagnosis, SEP modi-
fied the distance-late-stage association (p for interaction = .006), but
SEP did not modify the distance-delay association (p for
interaction = .37, Supplementary Table 2). The distance-late-stage
association was observed in women with higher SEP (OR = 1.71, 95%
CI: 1.19-2.43) and not in those with lower SEP, but the latter group
had later stage regardless of residential location. Similar results were
observed in analysis restricted to non-Nigerian women. No effect
modification by rural residence was found (p for interaction >.65
for all).
Finally, the exploratory analysis in Namibia showed that among
women living outside Windhoek, those living more than 50 km from
the nearest pathological laboratory had elevated odds of delay in diag-
nosis than those living <50 km from the nearest pathological labora-
tory after adjusting for age at diagnosis, educational status and SEP
(OR = 1.54, 95% CI: 0.93-2.57, Supplementary Table 3). The
TABLE 1 (Continued)
Population Total Namibia black Namibia non-black Nigeria Uganda Zambia
Self-perceived barriers to diagnostic delay (yes)f
Transport 192 (13) 31 (8) 0 (0) 20 (5) 98 (24) 43 (21)
Hospital too far 125 (8) 6 (2) 1 (1) 40 (10) 55 (13) 23 (11)
Other obligations/no permission from family
member
33 (2) 2 (1) 0 (0) 18 (5) 9 (2) 4 (2)
Embarrassment 34 (2) 1 (0) 0 (0) 21 (5) 2 (0) 10 (5)
Pain or discomfort 89 (6) 0 (0) 0 (0) 26 (7) 42 (10) 21 (10)
Fear of dying/treatment 89 (6) 2 (1) 0 (0) 40 (10) 8 (2) 39 (19)
No trust in medicine/prefer traditional healer 56 (4) 3 (1) 1 (1) 36 (9) 12 (3) 4 (2)
Difficulty with making an appointment or reaching
a doctor
78 (5) 14 (4) 1 (1) 47 (12) 10 (2) 6 (3)
Cost of diagnostic tests/treatment 108 (7) 2 (1) 0 (0) 36 (9) 68 (16) 2 (1)
Any barrier 419 (28) 61 (15) 7 (7) 138 (35) 134 (32) 79 (39)
Early diagnosis of breast cancer outcomes to be
examined
Months between first symptom recognition and
diagnosis, median (IQR)f
7 (2.8, 16) 6.5 (2.4, 15.2) 2.0 (0.5, 5.5) 5.5 (2.2, 12) 11 (5.6, 20.7) 7.8 (2.9, 16.4)
Categories
<3 months 373 (26) 106 (28) 60 (61) 113 (31) 45 (12) 49 (25)
3 months or more 1044 (74) 267 (72) 38 (39) 255 (69) 340 (88) 144 (75)
Missing 101 24 6 30 31 10
Stage at breast cancer diagnosis
0-II 513 (36) 142 (36) 78 (75) 90 (24) 136 (36) 67 (41)
III or IV 902 (64) 255 (64) 26 (25) 279 (76) 247 (64) 95 (59)
Missing 103 0 0 29 33 41
Abbreviations: ABC-DO, the African Breast Cancer—Disparities in Outcomes; HCP, healthcare provider; IQR, interquartile range; km, kilometer; N, national; No,
number; S, state.
aSocioeconomic position score was constructed based on the total number of specific items possessed (eg, home ownership, indoor water, flush toilet, electricity,
vehicle).
bBreast cancer knowledge score was constructed based on the total number of correct answers given to five questions about breast cancer.
c“Breast cancer not suspected/tests done but no results” includes the women who reported having been told not to worry or that they had something else, or
undergone tests but never received the results. “Breast cancer suspected/referral” includes those who reported having been told that they had breast cancer or been
referred to a provider/facility outside the recruitment hospitals. “Went directly to the treatment facility” are those who went directly to one of the recruitment
hospitals.
dDistance to the nearest laboratory within the network of the National Institute of Pathology that provides diagnostic services was used for Namibian women who
did not go directly to the Windhoek Central Hospital. Distance to the Windhoek Central Hospital was used if they went directly to the hospital.
eThe question asked about the travel time on the day of the visit, which might not capture the entire journey from home to the treatment facility.
fIf time since first symptom recognition to diagnosis was 5 years or longer, the value was set to missing as it was assumed that the self-reported symptom(s) were
related to a previous condition.
TOGAWA ET AL. 2217
corresponding OR for black women was 1.60 (95% CI: 0.90-2.84). No
substantial difference in odds of being diagnosed at late stage was
observed between women living outside Windhoek and more than
50 km from the nearest pathological laboratory (OR: 1.16, 95% CI:
0.74-1.82) and those living outside Windhoek and <50 km from the
nearest pathological laboratory (reference group).
4 | DISCUSSION
Our study of women diagnosed with breast cancer in four SSA coun-
tries (Namibia, Nigeria, Uganda and Zambia) showed large distances
traveled and long travel time taken to reach cancer services, illustrat-
ing obstacles that women might face during their prediagnostic jour-
neys. The study further showed that the geospatial characteristics,
particularly travel distance to cancer diagnostic or treatment facilities,
were associated with both delay in diagnosis and more advanced
stage at diagnosis, with some heterogeneity across SSA settings and
by SEP.
The observed association between distance to cancer treatment
facility and late stage at diagnosis largely support the finding from a
recent review of 27 studies that greater travel burden is associated
with late cancer diagnosis and poorer outcomes.13 Of the 27 studies
reviewed, only one was from Africa. The results from the latter, which
recruited over 1000 women newly diagnosed with breast cancer at a
South African public hospital, are also in line with our finding that
greater distance to the tertiary hospital was associated with a later
stage at diagnosis.12 To our knowledge, no other studies have so far
examined the association between distance to cancer care service and
cancer stage at diagnosis in SSA, but geospatial barriers in access to
obstetrics care have been investigated more extensively. A systematic
review of 57 studies conducted in SSA concluded that women living
farther away from health facilities equipped to provide skilled care for
childbirth are less likely to use such service.14
F IGURE 1 Residential locations of participants and hospitals where they were recruited and received cancer care. Each blue dot represents a
location where at least one participant resided. The bar charts show the distribution of straight-line distance (Euclidean distance) to the
recruitment hospitals. The Euclidean distance from home to recruitment hospital was categorized as follows: A, <25, 25-49, ≥50 km for Nigeria,
B, <50, 50-249, ≥250 km for Uganda, and C,D, <50, 50-249, 250-499, ≥500 km for Namibia and Zambia. Disclaimer: The boundaries and names
shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health
Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or
boundaries
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TABLE 2 Characteristics of women by population-specific quartile of distance to the cancer treatment facility (recruitment hospital)
Population-specific quartile of distance to the cancer
treatment facilitya Quartile 1 (shortest) Quartile 2 Quartile 3 Quartile 4 (longest)
Total N = 1518 N (%) N (%) N (%) N (%) P valueb
Sociodemographic factors
Age at breast cancer diagnosis, mean (SD) 48.4 (12.6) 51.0 (14.1) 51.6 (14.7) 50.5 (13.4) .006
Ethnicity
Non-black 39 (38) 15 (14) 25 (24) 25 (24)
Black 385 (27) 324 (23) 361 (26) 344 (24) .08
Educational level
Primary school or less 146 (21) 166 (24) 194 (28) 175 (26)
Secondary/high school 164 (32) 105 (21) 128 (25) 112 (22)
Technical/university 114 (35) 68 (21) 64 (20) 82 (25) <.001
Country-specific tertiles of socioeconomic position scorec
Tertile 1 (lowest) 120 (18) 143 (22) 230 (35) 170 (26)
Tertile 2 166 (32) 128 (25) 101 (20) 116 (23)
Tertile 3 (highest) 138 (40) 68 (20) 55 (16) 83 (24) <.001
Patient type
Public 244 (26) 215 (23) 258 (28) 218 (23)
Private without insurance 112 (27) 78 (19) 101 (24) 129 (31)
Private with insurance 68 (42) 46 (28) 27 (17) 22 (13) <.001
Breast cancer knowledge score, mean (SD) 3.5 (0.9) 3.5 (0.8) 3.5 (0.8) 3.4 (0.8) .32
Geospatial and other characteristics of prediagnostic
journey
Urbanization of area of residence
Urban (town or city) 347 (43) 193 (24) 117 (14) 157 (19)
Rural (rural or village) 77 (11) 146 (21) 269 (38) 212 (30) <.001
Type of first HCP
Formal 404 (28) 318 (22) 362 (25) 345 (24)
Informal 20 (22) 21 (24) 24 (27) 24 (27) .70
Outcome of visit to the first HCP
Breast cancer not suspected/tests done but no results 118 (24) 117 (24) 124 (25) 134 (27)
Breast cancer suspected/referral 210 (28) 150 (20) 197 (27) 184 (25)
Went directly to the treatment facility (ie, place of
recruitment)
96 (34) 72 (25) 65 (23) 51 (18) .009
No. of HCP contacts before reaching the recruitment
hospital, mean (SD)
1.9 (1.7) 2.0 (1.8) 2.1 (1.7) 2.2 (1.7) .26
Means of transport to the first HCP
Car 99 (33) 75 (25) 53 (18) 75 (25)
Public transport 250 (29) 174 (20) 236 (27) 201 (23)
Walk 65 (22) 75 (26) 82 (28) 70 (24)
Other, missing 10 (16) 15 (24) 15 (24) 23 (37) .001
Means of transport to the treatment facility
Car 103 (43) 51 (21) 39 (16) 47 (20)
Public transport, foot 274 (30) 197 (21) 226 (25) 223 (24)
Transport provided by cancer association 18 (8) 65 (28) 85 (37) 64 (28)
Other, missing 29 (23) 26 (21) 36 (29) 35 (28) <.001
(Continues)
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Geospatial barriers to early breast cancer diagnosis are likely
multifactorial and partly attributable to financial and logistic chal-
lenges (eg, needing financial support, transport for traveling and
accommodation near the hospital) or others due to competing priori-
ties (eg, work, care of children). To reduce geospatial barriers to
healthcare access, measures to improve patients' transport or lower
its financial burden could be implemented.18 For instance, lowering
patient's financial burden of travel may be feasible at local level by
using community-based loan funds19 or transport provided by hospi-
tals. In Namibia, 46% of the study participants reached the Wind-
hoek Central Hospital, which provides a major National Oncology
center, via transport provided by the hospitals. Most of these
women were living far away from the Windhoek Central Hospital. In
Zambia and Uganda, 21% to 24% of women reported cost or avail-
ability of transport as a barrier contributing to delay in reaching the
treatment facility. In these settings, providing transport or financial
support to those living in a remote area as done in Namibia may
help narrow the gap in cancer care access. Further setting specific
investigation should be followed to inform interventions to be
implemented in each setting.
Another possible approach to reduce the barrier of distance to
cancer treatment facility is to decentralize part of the initial diagnostic
work-up to lower-level facilities, for instance, from national to district
level. Such partial decentralization of cancer diagnostic services is
being considered in Zambia20 and is recommended by the Breast
Health Global Initiative (BHGI) as a phased implementation step in
improving access to prompt and effective breast cancer diagnosis and
treatment.21 Namibia has a network of pathological laboratories
across the country that allows women to undergo biopsy and receive
diagnostic test results without having to travel to the central hospital;
instead, the FNA/tumor specimens are sent to the capital city and
only those women with a histological/cytological-confirmed diagnosis
need to travel to the central hospital for treatment. In the present
study, the median time from first symptom recognition to specimen
collection was longer (3.3 vs 6.2 months) (data not shown) and the
odds of having a delay to diagnosis and being diagnosed at late stage
were higher in women living outside Windhoek compared to those liv-
ing in Windhoek (Supplementary Table 3), but the median time from
specimen collection to presentation at the Windhoek Central Hospital
was similar (0.8 months and 1.1 months, respectively). Furthermore,
TABLE 2 (Continued)
Population-specific quartile of distance to the cancer
treatment facilitya Quartile 1 (shortest) Quartile 2 Quartile 3 Quartile 4 (longest)
Total N = 1518 N (%) N (%) N (%) N (%) P valueb
Distance in kilometer (median, IQR) from home to:
First HCP 1 (1, 6) 3 (1, 31) 12 (1, 73) 29 (1, 126) <.001
Diagnostic facility 2 (1, 6) 21 (3, 62) 27 (11, 135) 208 (33, 376) <.001
Travel time in hours (median, IQR) on the day of the visit
to:
First HCP 0.5 (0.3, 1) 0.7 (0.3, 1.2) 0.8 (0.4, 2) 1.0 (0.3, 2) <.001
Treatment facilityd 0.8 (0.4, 1) 2.0 (0.7, 4) 2.0 (1, 7) 1.5 (1, 7) <.001
Self-perceived barriers contributing to delay (yes)e
Transport 27 (6) 43 (13) 68 (18) 54 (15) <.001
Hospital too far 9 (2) 16 (5) 60 (16) 40 (11) <.001
Other obligations/no permission from family member 9 (2) 4 (1) 9 (2) 11 (3) .43
Embarrassment 7 (2) 9 (3) 8 (2) 10 (3) .72
Pain or discomfort 21 (5) 23 (7) 24 (6) 21 (6) .74
Fear of dying/treatment 30 (7) 21 (6) 22 (6) 16 (4) .43
No trust in medicine/prefer traditional healer 10 (2) 15 (4) 17 (4) 14 (4) .36
Difficulty with making an appointment or getting a hold
of doctor
10 (2) 17 (5) 29 (8) 22 (6) .008
Cost of diagnostic tests/treatment 24 (6) 25 (7) 31 (8) 28 (8) .57
Any barrier 84 (20) 93 (27) 140 (36) 102 (28) <.001
Abbreviations: HCP, healthcare provider; IQR, interquartile range.
aPopulation-specific quartile (Quartile 1, 2, 3, 4): Namibia black: 1-195, 196-457, 458-583, 584+ km; Namibia non-black: 1, 2-238, 239-292, 293+ km;
Nigeria: 1–2, 3–6, 7-28, 29+ km; Uganda: 1-15, 16-77, 78-196, 197+ km; Zambia: 3-8, 9-156, 157-374, 375+ km.
bP values were derived from ANOVA test for the continuous variables and Chi-square test for the categorical variables.
cCountry-specific tertile of socioeconomic position score (Tertile 1, 2, 3): Namibia: 0-4, 5-7, 8-9; Nigeria: 0-4, 5-6, 7-8; Uganda: 0-2, 3, 4-8; Zambia: 0-2, 3-
5, 6-8.
dThe question asked about the travel time on the day of the visit, which might not capture the entire journey from home to the treatment facility.
eParticipants could report more than one barrier.
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among black women living outside Windhoek, those who lived greater
than 50 km from a pathological laboratory had greater odds of delay
in diagnosis compared to those who lived less than 50 km from a
pathological laboratory. This is consistent with a positive effect of a
partial decentralization of cancer diagnostic services, that is,
decentralized tissue collection with centralized pathological review
contributing to improvement of access to early diagnosis of breast
cancer.
Alongside a full or partial decentralization of diagnostic services,
an effective system of referral to the diagnostic services, transport of
samples and result feedback, followed by referral for treatment should
also be in place. On a positive note, distance to first provider did not
contribute to delays or late stage, and many first providers were con-
tacted early in the prediagnostic journey.22 This first provider thus
represents a critical first interaction of the women with the health sys-
tem, a point at which interventions (financial assistance, guidance and
support) can be made to accelerate the subsequent journey to treat-
ment. The present study revealed that 32% of women were not
suspected of having breast cancer or were not referred for further
evaluation by the first healthcare provider visited and were more
likely to have a delay in diagnosis. This points to the need to improve
awareness and training about breast cancer symptoms and available
cancer services among healthcare providers throughout the referral
system10,23 while balancing against the burden of false positives, that
is, referring women with benign diseases for diagnostics and treat-
ment. As a nonnegligible proportion of women, particularly in Nigeria
(7%) and Uganda (13%), sought care from an informal care provider,
involving these providers in the pyramid of referrals should also be
considered to facilitate timely diagnosis and treatment.Additional
approaches to the improvement of breast cancer diagnosis and
pathology have been proposed by BHGI, the International Society of
Clinical Pathologists (ISCP) and others for resource-limited settings,
such as training pathologists and organizing international pathology
services.24,25
Among the settings examined in the ABC-DO study, we also
observed some heterogeneity with Nigeria having a particularly dis-
tinct profile. In this setting, women were recruited at the public hospi-
tals (the Federal Medical Centre in Owerri and university teaching
hospital in Aba) and at a private clinic in Aba, with 73% of the women
living within a radius of 25 km. Although the time from first symptom
recognition to diagnosis was shorter than that of other settings, the
proportion of women diagnosed at late stage was higher. The
geospatial association with late stage at diagnosis in Nigeria was
inconsistent to that seen in the other settings. The associations of late
stage at diagnosis with rural residence (Supplementary Table 1) and
higher quartiles of distance to treatment facility (data not shown)
were reversed. Although the peculiarity of distance-stage association
in Nigerian women appears to be driven by certain sites (data not
shown), the reasons for the discrepancy are unclear. The inverse asso-
ciations could be in part due to the small variations of distance and
stage, residual confounding from determinants of advanced stage at
diagnosis, such as educational and socioeconomic statuses,11 or dis-
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those with an advanced disease are less likely to reach the hospital if
they are living far away from the hospital. The latter raises an impor-
tant question about the extent of undiagnosed cases in the SSA set-
tings. Furthermore, we observed an effect modification of the
distance-stage association by SEP, with the proportion of late stage at
diagnosis being high regardless of distance in women with lower SEP,
suggesting that they might have additional obstacles that need to be
addressed in order to reduce delays in diagnosis. These heterogene-
ities underscore the importance of evaluating the specificities of each
population when designing measures for down-staging in SSA.
Unlike many of the previous studies of cancer diagnosis in SSA
settings, the present study featured geospatial dimension to
prediagnostic journey, which has been underinvestigated in cancer
care in SSA. The results of our study, together with the other key
determinants of delay in breast cancer diagnosis22 and advanced stage
at diagnosis11 (eg, lack of breast cancer awareness), can guide future
implementation research and governments and their partners to make
informed decisions about the planning and development of strategies
to mitigate breast cancer deaths in SSA settings.
Nevertheless, in interpreting the results of the present study,
potential limitations of the study must be considered. One of the limi-
tations of the study is that the geocodes were based on the names of
places that may cover a large area, making the locations less precise.
Some of the locations of diagnostic centers might also not be precise
if the samples were collected at another laboratory/clinic. Also, travel
distance was calculated based on straight-line distance and not on
road network, which can also introduce information bias. However, a
high correlation was observed between the straight-line distance and
road distance in a random sample of women from Uganda (r = 0.91,
data not shown). Therefore, the ranking of the distance is likely to
reflect that of the road distance. Furthermore, there is potential mis-
classification of the outcomes under study. We determined delay
based on date of first symptom recognition, which might not reflect
the date of symptom onset due to a lack of awareness about breast
cancer symptoms or a difficulty with remembering when. However, as
breast cancer knowledge score did not substantially differ by distance,
we would expect the resultant bias would be minimal. Another poten-
tial limitation is that the present study included only women who
attended the selected treatment facilities. Therefore, it is possible that
the stage distribution differs from what would be observed in the
totality of breast cancer cases in the respective countries. Also, under-
estimation of cancer stage was suspected in this cohort.4 Since all
women were staged at the treatment facility, the misclassification is
unlikely to be differential, and thus the results would be biased
towards the null. Nevertheless, given the large variety of distance in
SSA except in Nigeria, we were still able to capture the gradient of
distances and associated odds of delay in diagnosis and late stage at
diagnosis.
Although the focus of the present study was on geospatial bar-
riers to early diagnosis of breast cancer, such barriers can also delay
treatment or hinder adherence to treatment and receipt of other can-
cer services, such as follow-up examinations and counseling.13 The
efforts to tackle the geospatial barrier need to be extended to also
ensure access to care after a diagnosis and accompanied by ensuring
the availability of appropriate equipment, drugs and healthcare pro-
viders in order to achieve the aims to reduce the morbidity and mor-
tality of cancer and to improve the quality of life of the women
affected by breast cancer.27
F IGURE 2 Forest plot of the odds ratios (ORs) with corresponding 95% confidence intervals (CIs) of delay in diagnosis and late stage at
diagnosis on geospatial characteristics. ORs and CIs were derived from logistic regression models adjusted for urbanization of area of residence or
straight-line distance to diagnostic/treatment facility, modes of transport used to reach the first healthcare provider and the treatment facility,
population, age, educational status and socioeconomic position score. In the analysis of delay in diagnosis, distance to diagnostic facility was
examined, whereas in the analysis of late stage at diagnosis, distance to treatment facility was examined. The ORs for distance are based on the
comparison between the highest and lowest quartiles (with the lowest quartile as reference)
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5 | CONCLUSIONS
The present study provides evidence that geographical distance to
cancer care services is a barrier to early diagnosis of breast cancer in
SSA, indicating potential avenues for downstaging this disease. Poten-
tial approaches to reducing this barrier include providing transport or
travel allowance to women, particularly those living far away from the
hospitals, or considering decentralizing diagnostic services in conjunc-
tion with accelerated referral and follow-up. Population-specific inter-
ventions will be needed to develop targeted approaches to tackle
these barriers to early diagnosis of breast cancer.
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